Mexico Emerges as a Key Export Market While Strategic Acquisitions, New Product Development and Strong Domestic Formulations Position Pharma Company for Multi-Year Growth

RPG Life Sciences Ltd. is intensifying its global growth strategy by expanding its Active Pharmaceutical Ingredient (API) business across Mexico and other emerging markets, while simultaneously evaluating strategic acquisitions to strengthen its manufacturing capabilities and international footprint. Backed by a strong recovery in API production, healthy domestic formulations growth and a robust product pipeline, the pharmaceutical company remains confident of achieving its ambitious ₹1,000 crore revenue milestone by FY28.

The company reported a solid performance during the first quarter of FY27, with overall revenue rising 15.8% year-on-year to ₹195.7 crore, while EBITDA increased 17.9% to ₹48 crore. Margin expansion and accelerating API exports further strengthened investor confidence in the company's long-term strategy.

Management believes the next phase of growth will be driven by expanding exports, launching new APIs, strengthening international formulations and pursuing value-accretive acquisitions.

API Business Makes Strong Comeback

The API segment has emerged as one of the fastest-growing businesses for RPG Life Sciences following the restoration of operations at its Navi Mumbai manufacturing facility, which had been affected by a fire last year.

The recovery has enabled the company to regain production capacity and improve export momentum.

API Business Snapshot

Management expects APIs to continue growing faster than the company's overall business, gradually increasing their contribution to consolidated revenue over the next two years.

Mexico Becomes the Centrepiece of Export Strategy

Mexico has become one of RPG Life Sciences' most important overseas markets.

The company has established a dominant position in one of its key API categories, where it controls nearly 75% of the relevant market, making the country a strategic growth engine.

Strong customer relationships, regulatory approvals and consistent product quality have enabled RPG Life Sciences to build a significant competitive advantage in the region.

Going forward, management plans to deepen its presence in Mexico while identifying additional opportunities across Latin America.

Expanding Global Footprint Across Multiple Regions

RPG Life Sciences continues to diversify its international operations across developed and emerging pharmaceutical markets.

Key Export Markets

• Mexico

• Canada

• Japan

• United Kingdom

• Vietnam

• Philippines

• Select African nations

The company is also exploring additional high-growth markets where demand for quality APIs continues to increase due to expanding generic medicine manufacturing.

A geographically diversified export portfolio helps reduce concentration risk while creating multiple avenues for long-term growth.

Strategic Acquisitions Could Accelerate Expansion

Apart from organic growth, RPG Life Sciences is actively evaluating acquisition opportunities that complement its API business.

The company is particularly interested in acquiring USFDA-approved manufacturing assets, primarily within India, although it remains open to overseas opportunities if they offer strategic advantages.

Management reviews multiple acquisition opportunities every month and evaluates them based on:

• Regulatory approvals.

• Product portfolio fit.

• Manufacturing capabilities.

• Export potential.

• Operational synergies.

• Long-term value creation.

The company also believes that changing geopolitical dynamics are creating attractive opportunities to acquire high-quality pharmaceutical assets.

Innovation Pipeline Remains Strong

Research and product development continue to play a central role in RPG Life Sciences' growth strategy.

Management has drawn up a structured three-year API development roadmap, with plans to introduce at least five new APIs every year.

The strategy is expected to:

• Expand the product portfolio.

• Increase export opportunities.

• Improve customer retention.

• Support higher margins.

• Strengthen global competitiveness.

Continuous innovation is becoming increasingly important as pharmaceutical companies seek differentiated, high-value products.

Domestic Formulations Continue to Outperform

The domestic formulations business remains the company's largest revenue contributor and continues to deliver healthy growth.

During the June quarter, domestic formulations recorded growth of 14.8%, outperforming the overall Indian pharmaceutical market, which expanded by 11.6% during the same period.

Domestic Business Highlights

The outperformance reflects the strength of the company's brand portfolio and expanding market reach.

Naprosyn Continues to Strengthen Brand Portfolio

The company's flagship pain management brand Naprosyn remains a key contributor to domestic growth.

Naprosyn Performance

• Sales increased 16% during Q1 FY27.

• Targeted to become a ₹100 crore brand in FY27.

• New Naprosyn ES launched in India.

• Over-the-counter version planned for launch in Canada through Walmart.

The international launch of OTC products represents an important milestone in the company's global consumer healthcare strategy.

International Formulations Business Gains Momentum

RPG Life Sciences is also expanding its formulations business through strategic partnerships.

The company has entered into a Contract Development and Manufacturing Organisation (CDMO) agreement with a UK-based pharmaceutical company.

CDMO Project Highlights

• Three pharmaceutical products under development.

• Commercial launch expected within six months.

• Long-term manufacturing partnership.

• Additional export opportunities.

The CDMO business provides recurring revenue opportunities while improving capacity utilisation.

Financial Performance Reflects Healthy Operational Momentum

The company's financial results underline the effectiveness of its growth strategy.

Q1 FY27 Financial Performance

Higher operating leverage and improved business mix helped expand profitability during the quarter.

Roadmap to ₹1,000 Crore Revenue

Management remains optimistic about achieving ₹1,000 crore annual revenue by FY28.

Key Growth Drivers

• Faster API exports.

• Expansion in Mexico.

• Entry into new export markets.

• New API launches.

• Domestic formulations growth.

• Naprosyn brand expansion.

• CDMO business.

• Strategic acquisitions.

• Margin improvement.

A balanced mix of organic growth and inorganic expansion is expected to support the company's long-term ambitions.

India's API Industry Continues to Benefit from Structural Trends

The Indian pharmaceutical industry continues to gain from global supply chain diversification and increasing demand for reliable API suppliers.

Key industry growth drivers include:

• China-plus-one sourcing strategy.

• Rising generic medicine demand.

• Government support for domestic manufacturing.

• Production Linked Incentive (PLI) schemes.

• Expanding pharmaceutical exports.

• Greater focus on supply chain resilience.

Companies with established regulatory capabilities and diversified export markets are well positioned to benefit from these long-term trends.

Growth Opportunities Beyond FY28

Apart from achieving its near-term revenue target, RPG Life Sciences is building capabilities that could support sustainable long-term expansion.

Potential future opportunities include:

• Expansion into regulated markets.

• Larger CDMO partnerships.

• Specialty APIs.

• High-value formulations.

• Technology-driven manufacturing.

• Strategic international collaborations.

These initiatives could further strengthen the company's competitive position over the coming decade.

Risks Investors Should Monitor

Despite favourable growth prospects, investors should remain mindful of several challenges.

Key Risks

• Regulatory approvals.

• Delay in acquisitions.

• Currency fluctuations.

• Geopolitical uncertainties.

• Pricing pressure.

• Raw material inflation.

• Manufacturing disruptions.

• Competitive intensity.

Successful execution across multiple growth initiatives will remain the key factor influencing future earnings.

Why Investors Are Watching RPG Life Sciences

The company offers exposure to several long-term pharmaceutical growth themes:

• Expanding API exports.

• Diversified international operations.

• Strong domestic brands.

• Improving profitability.

• Consistent product innovation.

• Acquisition-led growth strategy.

• Global manufacturing opportunities.

These strengths position RPG Life Sciences to benefit from the evolving global pharmaceutical supply chain.

Key Highlights

Market Outlook

RPG Life Sciences is entering a stronger growth cycle supported by the recovery of its API operations, rising export demand and continued momentum in its domestic formulations business. The company's increasing focus on Mexico and other international markets, combined with its strategy of developing new APIs, expanding CDMO partnerships and pursuing strategic acquisitions, provides multiple avenues for long-term growth. With improving profitability, a healthier product mix and a clear roadmap to achieve ₹1,000 crore in revenue by FY28, the company appears well positioned to benefit from favourable global pharmaceutical trends. Investors will closely monitor API export growth, execution of acquisition opportunities, regulatory progress and the commercial success of new product launches as key indicators of the company's ability to sustain its growth trajectory over the coming years.